A Phase 2 interventional study of GWP42003 and Placebo in Ulcerative Colitis, sponsored by GW Research Ltd. Completed at 8 sites in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-08-09.
Sponsored by GW Research Ltd (part of Jazz Pharmaceuticals) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 215 studies in Colitis, Ulcerative with a site in United Kingdom — 29 open to participants now, 60 under way, 25 of them phase 3. Colitis, Ulcerative · United Kingdom.
Among the 215 studies in Colitis, Ulcerative with a site in United Kingdom, this one is the 135th largest by enrollment of the 178 interventional ones that give a count, is one of 9 that started in 2012, is one of 57 in phase 2, and was the 36th registered.
1,857 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.
Browse Colitis, Ulcerative studies →29 of the 215 studies in Colitis, Ulcerative with a site in United Kingdom are open now. Recruiting first, the newest first:
GlaxoSmithKline · Sites in United Kingdom
Ages 18–75
GlaxoSmithKline · Sites in United Kingdom
Ages 18–75
University of Nottingham · Sites in United Kingdom
Ages 16+
Hoffmann-La Roche · Sites in United Kingdom, United States, Belgium and 2 more countries
Ages 18–60
Pfizer · Sites in United Kingdom, United States, Australia and 7 more countries
Ages 2–11
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 305 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 135 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
215 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 19 · Phase 2 64 · Phase 3 72 · Phase 4 9
First in 2001; this study’s year is marked. 9 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 60 is below the median of 70 across 1,239 interventional studies indexed under Colitis, Ulcerative.
Median enrollment 143 across the 178 interventional studies, 334 across the 36 observational. Of the 143 that completed or were terminated, 83 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
161 of 215 have an industry lead sponsor. The 10 most frequent:
This study is registered under GW Research Ltd, one of the names counted as Jazz Pharmaceuticals. Under that name alone:
GW Research Ltd is the lead sponsor of 5 studies on the registry; none are open to participants now.
Jazz Pharmaceuticals has 1 study filed under Colitis, Ulcerative — fewer than ten, so there is no comparison to draw.
17 of the studies in Colitis, Ulcerative with a site in United Kingdom that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06589986Phase 3Hoffmann-La RocheA Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis | 2027-01-30 |
| NCT04624230Phase 3PfizerEvaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis | 2027-03-17 |
| NCT03006068Phase 3AbbVieA Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) | 2027-07 |
| NCT06880744Phase 3AbbVieA Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab | 2027-08 |
| NCT05092269Phase 3Janssen Research & Development, LLCA Long-term Extension Study of Ustekinumab in Pediatric Participants | 2027-09-29 |
Add all 17 to your calendar (.ics) → With an account.
Among the 215 studies in Colitis, Ulcerative with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study was conducted to determine the efficacy and safety of GWP42003 compared with placebo by the percentage of participants achieving remission quantified as a Mayo score of 2 or less (with no sub-score >1) after 10 weeks of treatment.
This study was conducted by GW Research Ltd as a pilot study to determine the efficacy and safety of GWP42003 (50 milligram [mg] up to 250 mg twice daily [BID]), compared with placebo, as assessed by the percentage of participants achieving remission quantified as a Mayo score of 2 or less (with no sub-score >1) after 10 weeks of treatment. This was the first study to determine whether the study drug has a positive benefit for participants on their ulcerative colitis symptom control, as well as effects on inflammatory marker cytokines (C reactive protein [CRP]), a fecal inflammatory marker (calprotectin), stool frequency, and rectal bleeding. In addition, various inflammatory bowel disease (IBD) questionnaires were implemented in the study to observe further benefits on the study drug, compared with placebo.
This study was multi-center, randomized, double-blind, placebo-controlled, and parallel-group. The study consisted of a 7-day baseline period, a 10-week treatment period, and a 1-week follow-up period. Each participant had a Mayo assessment (including endoscopy) conducted to confirm eligibility. Eligible participants were randomized in a 1:1 ratio into the GWP42003 and placebo groups. At the start of the treatment period, participants entered a 2-week dose escalation period to achieve their maximum tolerated dose, up to 250 mg BID in the GWP42003 group. Participants remained at the maximum tolerated dose for the rest of the treatment period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GWP42003 was administered orally at a dose of 50 mg up to 250 mg, BID, in the fasted state in the morning and evening, for 10 weeks. Following randomization, participants entered a 2-week dose escalation period to achieve their maximum tolerated dose, up to 500 mg, and maintained this dose for the rest of the treatment period. Participants were then followed for 1 week.
Drug: GWP42003
Placebo capsules matching the study drug were administered orally, BID, in the fasted state in the morning and evening, for 10 weeks. Participants were then followed for 1 week.
Drug: Placebo
1 to 5 50 mg capsules taken BID
Also known as: Cannabidiol (CBD) Botanical Drug Substance (BDS)
1 to 5 matching capsules taken BID
Also known as: Placebo control
Number Of Participants With A Mayo Score Of 2 Or Less (With No Sub-score >1) At EOT
The Mayo score is an assessment of ulcerative colitis activity. The Mayo total score ranges from 0 to 12 points with higher scores indicating more severe disease. The total score is made up of 4 sub-scores, each of which is assessed using a 0 to 3 scale. Sub-scores are graded as follows: Stool Frequency: 0 = Normal number of stools, 1 = 1 to 2 stools more than normal, 2 = 3 to 4 stools more than normal, 3 = 5 or more stools more than normal; Rectal Bleeding: 0 = No blood seen, 1 = Streaks of blood with stool less than half the time, 2 = Obvious blood with stool most of the time or more, 3 = Blood alone passes; Findings on Endoscopy: 0 = Normal or inactive disease, 1 = Mild disease (erythema, decreased vascular pattern, mild friability), 2 = Moderate disease (marked erythema, lack of vascular pattern, friability, erosions), 3 = Severe disease (spontaneous bleeding, ulceration); Physician's Global Assessment of Illness Severity (PGAS): 0 = none, 1 = mild, 2 = moderate, and 3 = severe.
Time frame: Baseline to End of Treatment (EOT) (10 weeks) or Early Termination (ET)
Number Of Participants With A Mayo Score Of 2 Or Less (With No Sub-score >1) At EOT - PP Analysis
The Mayo score is an assessment of ulcerative colitis activity. The Mayo total score ranges from 0 to 12 points with higher scores indicating more severe disease. The total score is made up of 4 sub-scores, each of which is assessed using a 0 to 3 scale. Sub-scores are graded as follows: Stool Frequency: 0 = Normal number of stools, 1 = 1 to 2 stools more than normal, 2 = 3 to 4 stools more than normal, 3 = 5 or more stools more than normal; Rectal Bleeding: 0 = No blood seen, 1 = Streaks of blood with stool less than half the time, 2 = Obvious blood with stool most of the time or more, 3 = Blood alone passes; Findings on Endoscopy: 0 = Normal or inactive disease, 1 = Mild disease (erythema, decreased vascular pattern, mild friability), 2 = Moderate disease (marked erythema, lack of vascular pattern, friability, erosions), 3 = Severe disease (spontaneous bleeding, ulceration); PGAS: 0 = none, 1 = mild, 2 = moderate, and 3 = severe.
Time frame: Baseline to EOT (10 weeks) or ET
Distribution On The PGAS At EOT
The PGAS required the physician to assess participants' disease severity on a 4-point scale (0=normal \[no disease\], 1 = mild disease, 2 = moderate disease, 3 = severe disease).
Time frame: EOT (10 weeks) or ET
Distribution On The PGAS At EOT - PP Analysis
The PGAS required the physician to assess participants' disease severity on a 4-point scale (0 = normal \[no disease\], 1 = mild disease, 2 = moderate disease, 3 = severe disease).
Time frame: EOT (10 weeks) or ET
Change From Baseline To EOT In The PGAS Score
The PGAS required the physician to assess participants' disease severity on a 4-point scale (0=normal \[no disease\], 1 = mild disease, 2 = moderate disease, 3 = severe disease). A negative change from Baseline indicates that symptoms decreased.
Time frame: Baseline to EOT (10 weeks) or ET
Change From Baseline To EOT In The PGAS Score - PP Analysis
The PGAS required the physician to assess participants' disease severity on a 4-point scale (0=normal \[no disease\], 1 = mild disease, 2 = moderate disease, 3 = severe disease). A negative change from Baseline indicates that symptoms decreased.
Time frame: Baseline to EOT (10 weeks) or ET
Change From Baseline To EOT In The Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score
The IBDQ is a validated and reliable tool to measure health-related quality of life in adult participants with inflammatory bowel disease (IBD). Each of the 32 questions falls into 1 of 4 domains (bowel symptoms, systemic symptoms, emotional status and social function). The 32 questions each have 7 possible responses. Each response is assigned a score ranging from 1 to 7, indicating the severity (1 being least favorable and 7 being the most favorable). Individual question scores were summed to give the IBDQ total score (range: 32 to 224 points). A positive change from Baseline indicates that symptoms improved.
Time frame: Baseline to EOT (10 weeks) or ET
Change From Baseline To EOT In The IBDQ Total Score - PP Analysis
The IBDQ is a validated and reliable tool to measure health-related quality of life in adult participants with IBD. Each of the 32 questions falls into 1 of 4 domains (bowel symptoms, systemic symptoms, emotional status and social function). The 32 questions each have 7 possible responses. Each response is assigned a score ranging from 1 to 7, indicating the severity (1 being least favorable and 7 being the most favorable). Individual question scores were summed to give the IBDQ total score (range: 32 to 224 points). A positive change from Baseline indicates that symptoms improved.
Time frame: Baseline to EOT (10 weeks) or ET
Number Of Participants Who Reported An Improvement In The Subject Global Impression Of Change (SGIC) Questionnaire At EOT
Participants were asked to answer the following question by using a 7-point scale (1 = very much better to 7 = very much worse): "Please assess the change in your ulcerative colitis symptoms since immediately before receiving the first dose of study treatment." Improvement was considered as very much better, much better, or minimally better.
Time frame: Visit 4 (Day 43) to EOT (10 weeks) or ET
Number Of Participants Who Reported An Improvement In The SGIC Questionnaire At EOT - PP Analysis
Participants were asked to answer the following question by using a 7-point scale (1 = very much better to 7 = very much worse): "Please assess the change in your ulcerative colitis symptoms since immediately before receiving the first dose of study treatment." Improvement was considered as very much better, much better, or minimally better.
Time frame: Visit 4 (Day 43) to EOT (10 weeks) or ET
Change From Baseline To The Last Week Of Treatment In Ulcerative Colitis Symptoms, As Measured By Scores On The Stool Frequency Numerical Rating Scale (NRS)
Participants were required to record their stool frequency during the baseline and treatment periods in a daily diary. Participants graded stool frequency with a 4-point NRS as follows: 0 = Normal number of stools; 1 = 1 to 2 stools more than normal; 2 = 3 to 4 stools more than normal; 3 = 5 or more stools more than normal. For analysis, the baseline value was defined as the mean stool frequency score of the last 7 available days of the baseline period; the EOT value was defined as the mean stool frequency score of last 7 days of the treatment period, or last 7 days for which study drug was taken, where earlier. A negative change from Baseline indicates that symptoms improved.
Time frame: Baseline to EOT (last 7 days) or ET
Change From Baseline To The Last Week Of Treatment In Ulcerative Colitis Symptoms, As Measured By Scores On The Stool Frequency NRS - PP Analysis
Participants were required to record their stool frequency during the baseline and treatment periods in a daily diary. Participants graded stool frequency with a 4-point NRS as follows: 0 = Normal number of stools; 1 = 1 to 2 stools more than normal; 2 = 3 to 4 stools more than normal; 3 = 5 or more stools more than normal. For analysis, the baseline value was defined as the mean stool frequency score of the last 7 available days of the baseline period; the EOT value was defined as the mean stool frequency score of last 7 days of the treatment period, or last 7 days for which study drug was taken, where earlier. A negative change from Baseline indicates that symptoms improved.
Time frame: Baseline to EOT (last 7 days) or ET
Change From Baseline To The Last Week Of Treatment In Ulcerative Colitis Symptoms, As Measured By Scores On The Rectal Bleeding NRS
Participants were required to record their rectal bleeding during the baseline and treatment periods in a daily diary. Participants graded rectal bleeding with a 4-point NRS as follows: 0 = No blood seen, 1 = Streaks of blood with stool less than half the time, 2 = Obvious blood with stool most of the time or more, 3 = Blood alone passes. For analysis, the baseline value was defined as the mean rectal bleeding score of the last 7 available days of the baseline period; the EOT value was defined as the mean rectal bleeding score of last 7 days of the treatment period, or last 7 days for which study drug was taken, where earlier. A negative change from Baseline indicates that symptoms improved.
Time frame: Baseline to EOT (last 7 days) or ET
Change From Baseline To The Last Week Of Treatment In Ulcerative Colitis Symptoms, As Measured By Scores On The Rectal Bleeding NRS - PP Analysis
Participants were required to record their rectal bleeding during the baseline and treatment periods in a daily diary. Participants graded rectal bleeding with a 4-point NRS as follows: 0 = No blood seen, 1 = Streaks of blood with stool less than half the time, 2 = Obvious blood with stool most of the time or more, 3 = Blood alone passes. For analysis, the baseline value was defined as the mean rectal bleeding score of the last 7 available days of the baseline period; the EOT value was defined as the mean rectal bleeding score of last 7 days of the treatment period, or last 7 days for which study drug was taken, where earlier. A negative change from Baseline indicates that symptoms improved.
Time frame: Baseline to EOT (last 7 days) or ET
Change From Baseline To EOT In The Mayo Total Score
The Mayo score is an assessment of ulcerative colitis activity. The Mayo total score ranges from 0 to 12 points with higher scores indicating more severe disease. The total score is made up of 4 sub-scores (assessed using a 0 to 3 scale). The sub-scores are graded as follows: Stool Frequency: 0 = Normal number of stools, 1 = 1 to 2 stools more than normal, 2 = 3 to 4 stools more than normal, 3 = 5 or more stools more than normal; Rectal Bleeding: 0 = No blood seen, 1 = Streaks of blood with stool less than half the time, 2 = Obvious blood with stool most of the time or more, 3 = Blood alone passes; Findings on Endoscopy: 0 = Normal or inactive disease, 1 = Mild disease (erythema, decreased vascular pattern, mild friability), 2 = Moderate disease (marked erythema, lack of vascular pattern, friability, erosions), 3 = Severe disease (spontaneous bleeding, ulceration); PGAS: 0 = none, 1 = mild, 2 = moderate and 3 = severe. A negative change from Baseline indicates that symptoms improved.
Time frame: Baseline to EOT (10 weeks) or ET
Change From Baseline To EOT In The Mayo Partial Score
The Mayo score is an assessment of ulcerative colitis activity. The Mayo partial score does not include the endoscopy findings sub-score and ranges from 0 to 9 points with higher scores indicating more severe disease. The partial score is made up of 3 sub-scores (assessed by using a 0 to 3 scale). The sub-scores are graded as follows: Stool Frequency: 0 = Normal number of stools, 1 = 1 to 2 stools more than normal, 2 = 3 to 4 stools more than normal, 3 = 5 or more stools more than normal; Rectal Bleeding: 0 = No blood seen, 1 = Streaks of blood with stool less than half the time, 2 = Obvious blood with stool most of the time or more, 3 = Blood alone passes; PGAS: 0 = none, 1 = mild, 2 = moderate and 3 = severe. A negative change from Baseline indicates that symptoms improved.
Time frame: Baseline to EOT (10 weeks) or ET
Change From Baseline To EOT In Levels Of Fecal Calprotectin
Fecal calprotectin is a marker of inflammation. Standard methods were used to measure the levels of calprotectin in fecal samples collected at the end of baseline and treatment periods. A negative change from Baseline indicates that levels of fecal calprotectin decreased.
Time frame: Baseline to EOT (10 weeks) or ET
| Milestone | GWP42003 | Placebo |
|---|---|---|
| Started | 29 | 31 |
| Received at least 1 dose of study drug | 29 | 31 |
| Intent-to-treat (itt) analysis set | 29 | 31 |
| Per protocol (pp) analysis set | 17 | 27 |
| Completed | 16 | 23 |
| Not completed | 13 | 8 |
| Withdrew: Adverse event | 10 | 5 |
| Withdrew: Met withdrawal criteria | 3 | 2 |
| Withdrew: Withdrawal by subject | 0 | 1 |
The Mayo score is an assessment of ulcerative colitis activity. The Mayo total score ranges from 0 to 12 points with higher scores indicating more severe disease. The total score is made up of 4 sub-scores, each of which is assessed using a 0 to 3 scale. Sub-scores are graded as follows: Stool Frequency: 0 = Normal number of stools, 1 = 1 to 2 stools more than normal, 2 = 3 to 4 stools more than normal, 3 = 5 or more stools more than normal; Rectal Bleeding: 0 = No blood seen, 1 = Streaks of blood with stool less than half the time, 2 = Obvious blood with stool most of the time or more, 3 = Blood alone passes; Findings on Endoscopy: 0 = Normal or inactive disease, 1 = Mild disease (erythema, decreased vascular pattern, mild friability), 2 = Moderate disease (marked erythema, lack of vascular pattern, friability, erosions), 3 = Severe disease (spontaneous bleeding, ulceration); Physician's Global Assessment of Illness Severity (PGAS): 0 = none, 1 = mild, 2 = moderate, and 3 = severe.
| Participants | GWP42003 | Placebo |
|---|---|---|
| Number Of Participants With A Mayo Score Of 2 Or Less (With No Sub-score >1) At EOT | 8 | 8 |
The Mayo score is an assessment of ulcerative colitis activity. The Mayo total score ranges from 0 to 12 points with higher scores indicating more severe disease. The total score is made up of 4 sub-scores, each of which is assessed using a 0 to 3 scale. Sub-scores are graded as follows: Stool Frequency: 0 = Normal number of stools, 1 = 1 to 2 stools more than normal, 2 = 3 to 4 stools more than normal, 3 = 5 or more stools more than normal; Rectal Bleeding: 0 = No blood seen, 1 = Streaks of blood with stool less than half the time, 2 = Obvious blood with stool most of the time or more, 3 = Blood alone passes; Findings on Endoscopy: 0 = Normal or inactive disease, 1 = Mild disease (erythema, decreased vascular pattern, mild friability), 2 = Moderate disease (marked erythema, lack of vascular pattern, friability, erosions), 3 = Severe disease (spontaneous bleeding, ulceration); PGAS: 0 = none, 1 = mild, 2 = moderate, and 3 = severe.
| Participants | GWP42003 | Placebo |
|---|---|---|
| Number Of Participants With A Mayo Score Of 2 Or Less (With No Sub-score >1) At EOT - PP Analysis | 7 | 8 |
The PGAS required the physician to assess participants' disease severity on a 4-point scale (0=normal \[no disease\], 1 = mild disease, 2 = moderate disease, 3 = severe disease).
| Participants | GWP42003 | Placebo |
|---|---|---|
| Normal | 7 | 5 |
| Mild Disease | 13 | 11 |
| Moderate Disease | 6 | 12 |
| Severe Disease | 0 | 3 |
The PGAS required the physician to assess participants' disease severity on a 4-point scale (0 = normal \[no disease\], 1 = mild disease, 2 = moderate disease, 3 = severe disease).
| Participants | GWP42003 | Placebo |
|---|---|---|
| Normal | 6 | 5 |
| Mild Disease | 8 | 9 |
| Moderate Disease | 3 | 11 |
| Severe Disease | 0 | 2 |
The PGAS required the physician to assess participants' disease severity on a 4-point scale (0=normal \[no disease\], 1 = mild disease, 2 = moderate disease, 3 = severe disease). A negative change from Baseline indicates that symptoms decreased.
| units on a scale | GWP42003 | Placebo |
|---|---|---|
| Baseline | 1.7 ± 0.45 | 1.8 ± 0.48 |
| Final Visit | 1.0 ± 0.72 | 1.4 ± 0.89 |
| Change From Baseline | -0.8 ± 0.82 | -0.4 ± 0.95 |
The PGAS required the physician to assess participants' disease severity on a 4-point scale (0=normal \[no disease\], 1 = mild disease, 2 = moderate disease, 3 = severe disease). A negative change from Baseline indicates that symptoms decreased.
| units on a scale | GWP42003 | Placebo |
|---|---|---|
| Baseline | 1.8 ± 0.44 | 1.8 ± 0.51 |
| Final Visit | 0.8 ± 0.73 | 1.4 ± 0.88 |
| Change From Baseline | -0.9 ± 0.83 | -0.4 ± 0.97 |
The IBDQ is a validated and reliable tool to measure health-related quality of life in adult participants with inflammatory bowel disease (IBD). Each of the 32 questions falls into 1 of 4 domains (bowel symptoms, systemic symptoms, emotional status and social function). The 32 questions each have 7 possible responses. Each response is assigned a score ranging from 1 to 7, indicating the severity (1 being least favorable and 7 being the most favorable). Individual question scores were summed to give the IBDQ total score (range: 32 to 224 points). A positive change from Baseline indicates that symptoms improved.
| units on a scale | GWP42003 | Placebo |
|---|---|---|
| Baseline | 138.5 ± 32.37 | 129.1 ± 38.02 |
| Final Visit | 164.2 ± 29.13 | 146.8 ± 47.50 |
| Change From Baseline | 24.6 ± 35.51 | 16.7 ± 36.33 |
The IBDQ is a validated and reliable tool to measure health-related quality of life in adult participants with IBD. Each of the 32 questions falls into 1 of 4 domains (bowel symptoms, systemic symptoms, emotional status and social function). The 32 questions each have 7 possible responses. Each response is assigned a score ranging from 1 to 7, indicating the severity (1 being least favorable and 7 being the most favorable). Individual question scores were summed to give the IBDQ total score (range: 32 to 224 points). A positive change from Baseline indicates that symptoms improved.
| units on a scale | GWP42003 | Placebo |
|---|---|---|
| Baseline | 134.0 ± 35.58 | 134.0 ± 37.30 |
| Final Visit | 172.8 ± 28.52 | 150.5 ± 48.87 |
| Change From Baseline | 39.3 ± 39.81 | 15.4 ± 33.65 |
Participants were asked to answer the following question by using a 7-point scale (1 = very much better to 7 = very much worse): "Please assess the change in your ulcerative colitis symptoms since immediately before receiving the first dose of study treatment." Improvement was considered as very much better, much better, or minimally better.
| Participants | GWP42003 | Placebo |
|---|---|---|
| Visit 4 (Day 43) | 15 | 18 |
| Final Visit | 23 | 17 |
Participants were asked to answer the following question by using a 7-point scale (1 = very much better to 7 = very much worse): "Please assess the change in your ulcerative colitis symptoms since immediately before receiving the first dose of study treatment." Improvement was considered as very much better, much better, or minimally better.
| Participants | GWP42003 | Placebo |
|---|---|---|
| Visit 4 (Day 43) | 14 | 18 |
| Final Visit | 16 | 16 |
Participants were required to record their stool frequency during the baseline and treatment periods in a daily diary. Participants graded stool frequency with a 4-point NRS as follows: 0 = Normal number of stools; 1 = 1 to 2 stools more than normal; 2 = 3 to 4 stools more than normal; 3 = 5 or more stools more than normal. For analysis, the baseline value was defined as the mean stool frequency score of the last 7 available days of the baseline period; the EOT value was defined as the mean stool frequency score of last 7 days of the treatment period, or last 7 days for which study drug was taken, where earlier. A negative change from Baseline indicates that symptoms improved.
| units on a scale | GWP42003 | Placebo |
|---|---|---|
| Baseline | 1.50 ± 0.937 | 1.89 ± 0.814 |
| Last 7 Days | 1.05 ± 0.930 | 1.46 ± 0.888 |
| Change From Baseline | -0.43 ± 0.563 | -0.43 ± 0.816 |
Participants were required to record their stool frequency during the baseline and treatment periods in a daily diary. Participants graded stool frequency with a 4-point NRS as follows: 0 = Normal number of stools; 1 = 1 to 2 stools more than normal; 2 = 3 to 4 stools more than normal; 3 = 5 or more stools more than normal. For analysis, the baseline value was defined as the mean stool frequency score of the last 7 available days of the baseline period; the EOT value was defined as the mean stool frequency score of last 7 days of the treatment period, or last 7 days for which study drug was taken, where earlier. A negative change from Baseline indicates that symptoms improved.
| units on a scale | GWP42003 | Placebo |
|---|---|---|
| Baseline | 1.37 ± 0.875 | 1.81 ± 0.827 |
| Last 7 Days | 0.73 ± 0.689 | 1.36 ± 0.871 |
| Change From Baseline | -0.64 ± 0.497 | -0.45 ± 0.768 |
Participants were required to record their rectal bleeding during the baseline and treatment periods in a daily diary. Participants graded rectal bleeding with a 4-point NRS as follows: 0 = No blood seen, 1 = Streaks of blood with stool less than half the time, 2 = Obvious blood with stool most of the time or more, 3 = Blood alone passes. For analysis, the baseline value was defined as the mean rectal bleeding score of the last 7 available days of the baseline period; the EOT value was defined as the mean rectal bleeding score of last 7 days of the treatment period, or last 7 days for which study drug was taken, where earlier. A negative change from Baseline indicates that symptoms improved.
| units on a scale | GWP42003 | Placebo |
|---|---|---|
| Baseline | 0.96 ± 0.829 | 1.19 ± 0.816 |
| Last 7 Days | 0.48 ± 0.711 | 0.84 ± 0.863 |
| Change From Baseline | -0.44 ± 0.709 | -0.35 ± 0.794 |
Participants were required to record their rectal bleeding during the baseline and treatment periods in a daily diary. Participants graded rectal bleeding with a 4-point NRS as follows: 0 = No blood seen, 1 = Streaks of blood with stool less than half the time, 2 = Obvious blood with stool most of the time or more, 3 = Blood alone passes. For analysis, the baseline value was defined as the mean rectal bleeding score of the last 7 available days of the baseline period; the EOT value was defined as the mean rectal bleeding score of last 7 days of the treatment period, or last 7 days for which study drug was taken, where earlier. A negative change from Baseline indicates that symptoms improved.
| units on a scale | GWP42003 | Placebo |
|---|---|---|
| Baseline | 0.82 ± 0.682 | 1.16 ± 0.831 |
| Last 7 Days | 0.24 ± 0.367 | 0.80 ± 0.875 |
| Change From Baseline | -0.58 ± 0.793 | -0.35 ± 0.773 |
The Mayo score is an assessment of ulcerative colitis activity. The Mayo total score ranges from 0 to 12 points with higher scores indicating more severe disease. The total score is made up of 4 sub-scores (assessed using a 0 to 3 scale). The sub-scores are graded as follows: Stool Frequency: 0 = Normal number of stools, 1 = 1 to 2 stools more than normal, 2 = 3 to 4 stools more than normal, 3 = 5 or more stools more than normal; Rectal Bleeding: 0 = No blood seen, 1 = Streaks of blood with stool less than half the time, 2 = Obvious blood with stool most of the time or more, 3 = Blood alone passes; Findings on Endoscopy: 0 = Normal or inactive disease, 1 = Mild disease (erythema, decreased vascular pattern, mild friability), 2 = Moderate disease (marked erythema, lack of vascular pattern, friability, erosions), 3 = Severe disease (spontaneous bleeding, ulceration); PGAS: 0 = none, 1 = mild, 2 = moderate and 3 = severe. A negative change from Baseline indicates that symptoms improved.
| units on a scale | GWP42003 | Placebo |
|---|---|---|
| Baseline | 6.3 ± 1.73 | 7.0 ± 2.01 |
| Final Visit | 3.0 ± 2.25 | 4.9 ± 3.22 |
| Change From Baseline | -3.0 ± 2.40 | -1.8 ± 2.73 |
The Mayo score is an assessment of ulcerative colitis activity. The Mayo partial score does not include the endoscopy findings sub-score and ranges from 0 to 9 points with higher scores indicating more severe disease. The partial score is made up of 3 sub-scores (assessed by using a 0 to 3 scale). The sub-scores are graded as follows: Stool Frequency: 0 = Normal number of stools, 1 = 1 to 2 stools more than normal, 2 = 3 to 4 stools more than normal, 3 = 5 or more stools more than normal; Rectal Bleeding: 0 = No blood seen, 1 = Streaks of blood with stool less than half the time, 2 = Obvious blood with stool most of the time or more, 3 = Blood alone passes; PGAS: 0 = none, 1 = mild, 2 = moderate and 3 = severe. A negative change from Baseline indicates that symptoms improved.
| units on a scale | GWP42003 | Placebo |
|---|---|---|
| Baseline | 4.4 ± 1.57 | 5.1 ± 1.61 |
| Final Visit | 2.3 ± 1.73 | 3.8 ± 2.60 |
| Change From Baseline | -2.0 ± 2.00 | -1.2 ± 2.14 |
Fecal calprotectin is a marker of inflammation. Standard methods were used to measure the levels of calprotectin in fecal samples collected at the end of baseline and treatment periods. A negative change from Baseline indicates that levels of fecal calprotectin decreased.
| microgram calprotectin/gram feces (ug/g) | GWP42003 | Placebo |
|---|---|---|
| Baseline | 490.6 ± 197.41 | 462.3 ± 227.35 |
| Final Visit | 397.3 ± 241.08 | 428.0 ± 229.38 |
| Change from Baseline | -91.6 ± 295.77 | -51.3 ± 289.32 |
The Mayo score is an assessment of ulcerative colitis activity. The Mayo total score ranges from 0 to 12 points with higher scores indicating more severe disease. The total score is made up of 4 sub-scores (assessed using a 0 to 3 scale). The sub-scores are graded as follows: Stool Frequency: 0 = Normal number of stools, 1 = 1 to 2 stools more than normal, 2 = 3 to 4 stools more than normal, 3 = 5 or more stools more than normal; Rectal Bleeding: 0 = No blood seen, 1 = Streaks of blood with stool less than half the time, 2 = Obvious blood with stool most of the time or more, 3 = Blood alone passes; Findings on Endoscopy: 0 = Normal or inactive disease, 1 = Mild disease (erythema, decreased vascular pattern, mild friability), 2 = Moderate disease (marked erythema, lack of vascular pattern, friability, erosions), 3 = Severe disease (spontaneous bleeding, ulceration); PGAS: 0 = none, 1 = mild, 2 = moderate, and 3 = severe. A negative change from Baseline indicates that symptoms improved.
| units on a scale | GWP42003 | Placebo |
|---|---|---|
| Baseline | 6.0 ± 1.70 | 6.8 ± 2.04 |
| Final Visit | 2.8 ± 2.02 | 4.7 ± 3.24 |
| Change From Baseline | -3.2 ± 2.25 | -1.9 ± 2.81 |
The Mayo score is an assessment of ulcerative colitis activity. The Mayo partial score does not include the endoscopy findings sub-score and ranges from 0 to 9 points with higher scores indicating more severe disease. The partial score is made up of 3 sub-scores (assessed by using a 0 to 3 scale). The sub-scores are graded as follows: Stool Frequency: 0 = Normal number of stools, 1 = 1 to 2 stools more than normal, 2 = 3 to 4 stools more than normal, 3 = 5 or more stools more than normal; Rectal Bleeding: 0 = No blood seen, 1 = Streaks of blood with stool less than half the time, 2 = Obvious blood with stool most of the time or more, 3 = Blood alone passes; PGAS: 0 = none, 1 = mild, 2 = moderate, and 3 = severe. A negative change from Baseline indicates that symptoms improved.
| units on a scale | GWP42003 | Placebo |
|---|---|---|
| Baseline | 4.1 ± 1.50 | 4.9 ± 1.63 |
| Final Visit | 1.7 ± 1.53 | 3.7 ± 2.66 |
| Change From Baseline | -2.4 ± 2.03 | -1.2 ± 2.17 |
Fecal calprotectin is a marker of inflammation. Standard methods were used to measure the levels of calprotectin in fecal samples collected at the end of baseline and treatment periods. A negative change from Baseline indicates that levels of fecal calprotectin decreased.
| ug/g | GWP42003 | Placebo |
|---|---|---|
| Baseline | 527.9 ± 164.14 | 440.3 ± 237.99 |
| Final Visit | 355.9 ± 247.75 | 408.9 ± 238.94 |
| Change From Baseline | -155.9 ± 306.84 | -51.9 ± 311.56 |
Collected over Post-dose on Day 1 through 14 days after the final dose (up to 85 days).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| GWP42003 | — | 0/29 (0%) | 28/29 (96.6%) |
| Placebo | — | 4/31 (12.9%) | 23/31 (74.2%) |
| Event | GWP42003 | Placebo |
|---|---|---|
| PregnancyPregnancy, puerperium and perinatal conditions | 0/6 | 1/10 |
| Colitis ulcerativeGastrointestinal disorders | 0/29 | 2/31 |
| Chest painGeneral disorders | 0/29 | 1/31 |
| Event | GWP42003 | Placebo |
|---|---|---|
| DizzinessNervous system disorders | 12/29 | 3/31 |
| SomnolenceNervous system disorders | 10/29 | 2/31 |
| NauseaGastrointestinal disorders | 8/29 | 3/31 |
| Disturbance in attentionNervous system disorders | 5/29 | 0/31 |
| Abdominal painGastrointestinal disorders | 1/29 | 5/31 |
| Dry mouthGastrointestinal disorders | 4/29 | 0/31 |
| VomitingGastrointestinal disorders | 4/29 | 0/31 |
| FatigueGeneral disorders | 4/29 | 4/31 |
| HeadacheNervous system disorders | 4/29 | 4/31 |
| DisorientationPsychiatric disorders | 4/29 | 0/31 |
Intent-to-treat (ITT) analysis set: all participants who were randomized and received at least 1 dose of study drug. Participants were analyzed according to the group to which they were randomized.
| Age, Continuous(years) | GWP42003 | Placebo | Total |
|---|---|---|---|
| Mean | 44.78 ± 15.050 | 42.82 ± 12.916 | 43.77 ± 13.903 |
| Sex: Female, Male(Participants) | GWP42003 | Placebo | Total |
|---|---|---|---|
| Female | 6 | 10 | 16 |
| Male | 23 | 21 | 44 |
Ran from May 2012 to primary completion in Aug 2014, 26 months.
Results were first posted in Aug 2015, 1 year after primary completion.
Of 110 industry-sponsored phase 2 interventional studies under Colitis, Ulcerative, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 35. This study's 26 months is close to that.
Counting every sponsor, half of 154 studies reached it within 28 months; a quarter within 22 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cannabidiol